Skip to main content

Advertisement

Log in

Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin’s lymphoma (NHL)

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Patients with systemic lupus erythematosus (SLE) are at increased risk of developing non-Hodgkin’s lymphoma (NHL), but features of SLE associated with NHL are not well described. The objective of this study was to describe SLE characteristics, laboratory serologies, and medication histories in patients who subsequently develop NHL. Two thousand twenty patients with SLE were identified using the online Partners’ patient database research tool between October 1992 and June 2005. We confirmed the diagnoses of SLE and NHL and sought details of medical history and treatment by medical record review. Eleven patients with NHL without coexisting rheumatoid arthritis, Sjögren’s, or HIV were identified; seven of these (64%) had a diffuse large B cell lymphoma subtype, and 83% of those stained were Epstein–Barr virus (EBV) negative. The mean duration of SLE at NHL diagnosis was 17.8 years (range 1.6–41.8), and the mean Systemic Lupus International Collaborative Clinics/American College of Rheumatology damage index was 1.9. Seven patients (64%) had SLE hematologic involvement, four had anti-dsDNA antibodies, and four had anti-phospholipid antibodies. One patient had significant renal disease. All patients had arthritis and had received antimalarial therapy. Five of 11 patients had received other treatments for SLE, including cyclophosphamide, imuran, methotrexate, and/or sulfasalazine. Diffuse large B cell lymphoma was the most common subtype of NHL, and most were EBV negative. Although disease duration was fairly long and end organ damage moderately severe in this group of patients, renal disease and the use of immunosuppressive chemotherapeutic agents were rare and did not appear to confer an increased risk of NHL development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40:761–768

    Article  PubMed  CAS  Google Scholar 

  2. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR et al (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52:1481–1490

    Article  PubMed  CAS  Google Scholar 

  3. Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:2337–2344

    Article  PubMed  Google Scholar 

  4. Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus 10:394–400

    Article  PubMed  CAS  Google Scholar 

  5. Bernatsky S, Ramsey-Goldman R, Clarke A (2005) Exploring the links between systemic lupus erythematosus and cancer. Rheum Dis Clin North Am 31:387–402, viii–ix

    Article  PubMed  Google Scholar 

  6. Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin JF, Joseph L, Lachance S, Cournoyer D, Zoma A, Manzi S, Ginzler E et al (2005) Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum Dis 64:1507–1509

    Article  PubMed  CAS  Google Scholar 

  7. Lofstrom BBC, Sundstrom C, Ekbom A, Lundberg I (2005) Lymphoma subtypes and prognosis in patients with systemic lupus erythematosus [abstract]. Arthritis Rheum 52:S726

    Google Scholar 

  8. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundstrom C, Akerman M, Melbye M, Glimelius B et al (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98:51–60

    Article  PubMed  Google Scholar 

  9. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  PubMed  CAS  Google Scholar 

  10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  PubMed  CAS  Google Scholar 

  11. Jaffe EHN, Stein H, Vardiman J (eds) (2001) World Health Organization classification of tumours. IARC Press, Lyon

    Google Scholar 

  12. Stoll T, Seifert B, Isenberg DA (1996) SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 35:248–254

    Article  PubMed  CAS  Google Scholar 

  13. Bjornadal L, Lofstrom B, Yin L, Lundberg IE, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31:66–71

    Article  PubMed  Google Scholar 

  14. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA (2004) Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus—a 5-yr prospective study. Rheumatology (Oxford) 43:1039–1044

    Article  CAS  Google Scholar 

  15. Alarcon GS, Roseman JM, McGwin G Jr, Uribe A, Bastian HM, Fessler BJ, Baethge BA, Friedman AW, Reveille JD (2004) Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford) 43:202–205

    Article  CAS  Google Scholar 

  16. Keeling DM, Isenberg DA (1993) Haematological manifestations of systemic lupus erythematosus. Blood Rev 7:199–207

    Article  PubMed  CAS  Google Scholar 

  17. Nossent JC, Swaak AJ (1991) Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 80:605–612

    PubMed  CAS  Google Scholar 

  18. Worrall JG, Snaith ML, Batchelor JR, Isenberg DA (1990) SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. Q J Med 74:319–330

    PubMed  CAS  Google Scholar 

  19. Bloomfield CD, McKenna RW, Brunning RD (1976) Significance of haematological parameters in the non-Hodgkin’s malignant lymphomas. Br J Haematol 32:41–46

    PubMed  CAS  Google Scholar 

  20. Lim EJ, Peh SC (2000) Bone marrow and peripheral blood changes in non-Hodgkin’s lymphoma. Singap Med J 41:279–285

    CAS  Google Scholar 

  21. Love PE, Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 112:682–698

    PubMed  CAS  Google Scholar 

  22. Petri M, Rheinschmidt M, Whiting-O’Keefe Q, Hellmann D, Corash L (1987) The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med 106:524–531

    PubMed  CAS  Google Scholar 

  23. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) (2004) Practical rheumatology. Mosby

  24. Jonsen A, Bengtsson AA, Nived O, Ryberg B, Sturfelt G (2002) Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology (Oxford) 41:1308–1312

    Article  CAS  Google Scholar 

  25. Alarcon GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, Bastian HM, Friedman AW, Reveille JD (2001) Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 44:2797–2806

    Article  PubMed  CAS  Google Scholar 

  26. Bastian HM, Roseman JM, McGwin G Jr, Alarcon GS, Friedman AW, Fessler BJ, Baethge BA, Reveille JD (2002) Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 11:152–160

    Article  PubMed  CAS  Google Scholar 

  27. Fisher SG, Fisher RI (2004) The epidemiology of non-Hodgkin’s lymphoma. Oncogene 23:6524–6534

    Article  PubMed  CAS  Google Scholar 

  28. Pettersson T, Pukkala E, Teppo L, Friman C (1992) Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51:437–439

    Article  PubMed  CAS  Google Scholar 

  29. Alarcon GS, McGwin G Jr, Bastian HM, Roseman J, Lisse J, Fessler BJ, Friedman AW, Reveille JD (2001) Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 45:191–202

    Article  PubMed  CAS  Google Scholar 

  30. Baecklund E, Sundstrom C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, Klareskog L (2003) Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 48:1543–1550

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

We would like to thank Danielle Blanch and Bill Reichman for their assistance with data management and Anthony Reginato, M.D., Ph.D. for his help with data collection.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jennifer K. King.

Rights and permissions

Reprints and permissions

About this article

Cite this article

King, J.K., Costenbader, K.H. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin’s lymphoma (NHL). Clin Rheumatol 26, 1491–1494 (2007). https://doi.org/10.1007/s10067-006-0532-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0532-7

Keywords

Navigation